Abstract 128P
Background
Biliary tract cancers are heterogeneous tumors defined by the anatomical location, intrahepatic, cholangiocarcinoma (ICC), extrahepatic (ECC), gallbladder and ampulla of Vater cancer (AVC).The outcome of treatment by location remains unclear in Latin American population, resulting in inconsistently data to enhance treatment decisions and outcome. The aim of this study is to describe the epidemiological features and prognosis of overall survival of Latin American population with biliary tract cancers.
Methods
Retrospective, observational study. Included patients treated at the National Cancer Institute between 2008 and 2022. Statistical analysis required: X2 and t test, Kaplan Meier, Log Rank and Cox Regression. Statistical significance differences were assessed when p was bilaterally <0.05.
Results
A total 786 of patients diagnosed with biliary tract cancer were included in the analysis. Patients had a median age of 61 years (24-96). Alcohol consumption and smoking were observed in 22% and 29% respectively. Regarding comorbidities, 22% had Type2DM, 27% HAS, and obesity & overweight was present in 13% and 32% respectively. Anatomical location included ICC (19%;n=151), ECC (22%;n=172), gallbladder (33%;n=259) and AVC (26%;n=204). Female were more prevalent in gallbladder and ICC (79% & 71%) (p<0.001). Median time to diagnosis was 3 months (0–120); extent of disease was observed as localized (18%;n=144), local-advanced (20%;n=158), and metastatic (60%;n=472). In metastatic patients, mean number of metastasis was 1 (1-7), being liver (66%), retroperitoneum (7%), and lung (6%) the most frequent sites. Comparing Chemotherapy and extent of disesase, 35%, 53%, and 55% patients received treatment for localized, unresectable, and metastatic (p=0.001). An OS analysis was conducted considering location, ICC patients showed a median-OS of 9months, ECC a median-OS of 12months, gallbladder a median-OS of 1months and AVC did not reach median-OS (p<0.001).
Conclusions
Prognosis and outcome for patients with biliary tract cancer differ depending on the anatomical subsite. This is one of the main studies describing epidemiological features, and outcome in Latin American patients with biliary tract.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17
117P - Genomic landscape of biliary tract cancers from India show distinct geographic variation
Presenter: Nitesh Rohatgi
Session: Poster session 17
118P - Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Presenter: Yeonghak Bang
Session: Poster session 17
119P - Management of biliary tract cancers in older patients: A French multicenter cohort study
Presenter: Marine Valery
Session: Poster session 17
120P - Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Presenter: Antoine Lebeaud
Session: Poster session 17
121P - PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Presenter: Blandine Delaunay
Session: Poster session 17
122P - Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Presenter: Umair Mahmood
Session: Poster session 17
123P - Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Presenter: Gwangil Kim
Session: Poster session 17
124P - Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Maria Bensi
Session: Poster session 17
125P - Real-world treatment patterns in patients with biliary tract cancer (BTC): Retrospective chart review survey in Europe (GARNET-2)
Presenter: John Bridgewater
Session: Poster session 17